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Abstract 36 
Angiotensin Converting Enzyme (ACE) is expressed in human skeletal muscle.  The ACE I/D 37 
polymorphism has been associated with athletic performance in some studies. Studies 38 
suggested that the ACE I/D gene variant is associated with ACE enzyme content in the serum, 39 
and there is an interaction between ACE and Uncoupling Proteins 2 and 3 (UCP2, and 40 
UCP3). However, no studies have explored the effect of ACE I/D on ACE, UCP2 and UCP3 41 
protein content in human skeletal muscle. Utilising the Gene SMART cohort (n=81), we 42 
investigated whether the ACE I/D gene variant is associated with ACE enzyme content in 43 
blood, and ACE, UCP2, and UCP3 protein content in skeletal muscle at baseline, and 44 
following a session of High-Intensity Interval Exercise (HIIE). Using a stringent and robust 45 
statistical analyses, we found that the ACE I/D gene variant was associated with ACE enzyme 46 
content in blood (p<0.005) at baseline, but not the ACE, UCP2, and UCP3 protein content in 47 
muscle at baseline. A single session of HIIE tended (0.005 < p < 0.05) to increase blood ACE 48 
content immediately post exercise, while muscle ACE protein content was lower 3 hours post  49 
a single session of HIIE (p<0.005). Muscle UCP3 protein content decreased immediately post 50 
a single session of HIIE (p<0.005), and remained low 3 hours post exercise. However, those 51 
changes in the muscle were not genotype-dependent. In conclusion, The ACE I/D gene 52 
variant predicts ACE enzyme content in blood but not the  ACE, UCP2 and UCP3 protein 53 
content of human skeletal muscle. 54 
 55 
 56 
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 58 
New & Noteworthy: This paper described the association between ACE I/D gene variant and 59 
ACE protein content in blood and, ACE, UCP2 and UCP3 protein content in skeletal muscle 60 
at baseline and after exercise, in a large cohorts of healthy males. Our data suggest that ACE 61 
I/D is strong predictor of blood ACE content but not muscle ACE content. 62 
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1. Introduction 63 
Angiotensin Converting Enzyme (ACE) is a key enzyme of the renin–angiotensin systems 64 
(RAS). ACE is cleaved from an anchoring stalk of endothelial cells that line blood vessels 65 
and is released into the blood circulation (10). ACE then cleaves angiotensin I (Ang I), a 66 
weak vasoconstrictor, into angiotensin II (Ang II), a much stronger one that triggers the 67 
release of aldosterone (26). Ang II exerts its agonist effect on angiotensin II type 1 receptor 68 
(AT1R), and leads to an increased blood pressure (27). ACE is also expressed in skeletal 69 
muscle (18), and is associated with increased  blood pressure and glucose homeostasis (11). 70 
ACE has been shown to influence exercise capacity (18). ACE inhibition increases peak 71 
aerobic capacity in patients with congestive heart failure (CHF) (12). ACE inhibitors were 72 
reported to improve peak oxygen capacity (VO2) in CHF by reducing the limitation from 73 
peripheral muscle factors (17). The ACE I/D gene variant, insertion (the I allele) or deletion 74 
(the D allele) of an Alu sequence of 287 base pairs in intron 16 of the ACE gene, has been 75 
identified three decades ago (33). The I allele was reported to be associated with endurance 76 
performance in high-altitude mountaineers (24). This association between I allele and 77 
endurance capacity was subsequently replicated in elite athletes (25, 27). However, 78 
conflicting results exist in literature (30, 38), suggesting that this association requires 79 
biological/physiological confirmation. Indeed, Rigat et al (33) reported that people who 80 
harbour the DD genotype has ~50% higher level of the ACE enzyme content in blood, 81 
compared with their II counterparts. Danser et al. also showed that carriers of the D allele 82 
have higher ACE enzyme activity in the heart (8). It is, however, unclear if the ACE I/D gene 83 
polymorphism influences the ACE protein content in human skeletal muscle. 84 
Studies suggested that there is an interaction between ACE and the mitochondrial Uncoupling 85 
Proteins 2 and 3 (UCP2, and UCP3). UCP2 and UCP3 are expressed in skeletal muscle and 86 
are involved in the regulation of muscle metabolism (34). An animal study reported that 87 
AT1R antagonist treatment downregulated UCP2 expression in mouse pancreas (6). Deletion 88 
of the angiotensin II type 2 receptor (AT2R) was reported to induce gene expression of UCP2 89 
and UCP3 in mouse skeletal muscle (42). A recent study further demonstrated that UCP2 90 
regulates ACE gene expression directly (10). RNA interference against UCP2 in human 91 
umbilical vein endothelial cells resulted in a higher ACE mRNA expression (10). Yet, no 92 
studies have explored the effect of ACE I/D gene polymorphism on UCP2 and UCP3 protein 93 
content in human skeletal muscle. 94 
When skeletal muscle is engaged in endurance work, there is a need to maintain blood 95 
pressure control and glucose homeostasis (11). The ACE enzyme is critical for optimal 96 
regulation of muscle bioenergetics and the maintenance of blood and glucose homeostasis 97 
(11). Importantly, twenty minutes of bicycle exercise at 70% VO2max resulted in elevated 98 
serum ACE activity (39). Yet, it is unknown how exercise influences ACE protein content in 99 
skeletal muscle. UCP2 and UCP3, on the other hand, have a rapid turnover (2). Acute 100 
exercise tends to decrease muscle UCP2 gene expression (36), and induces the mRNA 101 
expression of UCP3, but not UCP3 protein content (35). However, it is still unclear whether 102 
the ACE I/D polymorphism is associated with decreased/increased ACE, UCP2 and UCP3 103 
protein content in human skeletal muscle in response to acute exercise. 104 
Therefore, the aims of this study were to investigate whether: 1) the ACE I/D gene variant is 105 
associated with physiological characteristics (such as Peak Oxygen Uptake (VO2peak), Lactate 106 
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Threshold (LT), Power Peak  (Wpeak)) at baseline (i.e.; pre-exercise); 2) the ACE I/D gene 107 
variant is associated with ACE enzyme content in blood, and ACE, UCP2, and UCP3 protein 108 
content in skeletal muscle at baseline; and 3) the ACE I/D gene variant is associated with 109 
ACE enzyme content changes in blood, and ACE, UCP2, and UCP3 protein content changes 110 
in muscle following a single session of High-Intensity Interval Exercise (HIIE).  111 
2. Materials and Methods 112 
2.1 Study overview 113 
This study is part of a large multi-centre study, the Gene SMART study (Gene and Skeletal 114 
Muscle Adaptive Response to Training), which has been approved by Victoria University 115 
Human Ethics Committee (HRE13-223). The study methods were previously published 116 
elsewhere (40). Briefly, participants provided medical clearance to satisfy the predetermined 117 
study criteria prior to starting the study. Details regarding the study structure and protocol 118 
were then provided. Diet habits were assessed by questionnaire, and physical activity was 119 
monitored by accelerometers. Baseline exercise testings were conducted to determine 120 
baseline physical level. Baseline exercise testing comprised of two 20 km Time Trials (20 km 121 
TT) and three Graded Exercise Test to exhaustion (GXTs).  122 
Participants underwent a 48-h control diet prior to muscle biopsies to reduce confounding 123 
effects from diet. An experienced medical doctor collected a muscle biopsy from the vastus 124 
lateralis muscle, along with a blood sample from participants after 12h fasting. Immediately 125 
after the baseline resting biopsy, participants underwent a session of HIIE tailored to their 126 
baseline fitness on an electronically braked cycle ergometer (Velotron®, Racer Mate Inc, 127 
Seattle, USA). The exercise session comprised a 5-min warm-up at 60W and 8 high-intensity 128 
intervals of 2 min each, interspaced by 1-min rest periods at 60W (work:rest ratio = 2:1). For 129 
each participant, the intensity was calculated as LT + 40% of the difference between the 130 
participants’ individually determined Wpeak and the LT (LT + 40% (Wpeak-LT)). 131 
Immediately after the completion of the HIIE session, the second muscle biopsy and blood 132 
sample were collected. Three hours after the completion of the HIIE session, the third muscle 133 
biopsy and blood sample were collected. Participants remained fasted during the whole trial. 134 
The study flow is outlined in Figure 1. 135 
 136 
2.2 Participants 137 
Eighty-one unrelated moderately-trained males (Age: 31.0 ± 8.3, VO2peak: 46.3 ± 7.0 138 
mL/min/kg), Caucasian (for > 3 generations), aged 18-45, participated in the study. 139 
 140 
2.3 Nutrition consultation  141 
Each participant was provided with individualised, pre-packaged meals for the 48h prior to 142 
the biopsy day. The energy content of the provided meals were calculated using the Mifflin 143 
St-Jeor equation, which takes into account body mass, height, age and physical activity level 144 
(23). The macronutrient profile of the diet was based on the current Australian National 145 
Health and Medical Research Council (NHMRC) guidelines (i.e. 15-20% protein, 50-55% 146 
carbohydrates, < 30% fat and < 10% saturated fat). Participants were also required to refrain 147 
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from strenuous exercise, alcohol and caffeine consumption for the 48 h prior to the biopsy 148 
day. 149 
2.4 Performance tests 150 
Baseline performance tests were conducted as reported previously (22, 40). Briefly, all 151 
participants completed a familiarisation and baseline testing. All visits were separated by a 152 
minimum of 48 h. In addition, participants were required to refrain from exercise, alcohol and 153 
caffeine consumption for 24 h before all tests. The familiarisation and baseline testing 154 
consisted of the following: 155 
20km TT - During the first (familiarisation) and third visits (baseline test) participants 156 
performed a 20 km - TT on a Velotron
®
 cycle eogometer (RacerMate Inc. Seattle, WA, 157 
USA).  158 
GXT - During the second (familiarization), fourth and fifth visits participants conducted a 159 
GXT, to determine baseline LT and Wpeak. These tests were performed on an electronically 160 
braked cycle ergometer (Lode-excalibur sport, Groningen, the Netherlands) and consisted of 161 
4-min stages separated by 30-s rest periods until exhaustion. Capillary blood samples were 162 
taken at rest, after each completed stage, and immediately following exhaustion, and were 163 
analysed by a YSI 2300 STAT Plus system (Yellow Springs, Ohio, USA). LT was calculated 164 
by the modified DMAX method, as previously reported (4, 5).  165 
VO2peak test - After five min rest following the GXT, VO2peak was measured using a calibrated 166 
Quark CPET metabolic system (COSMED, Rome, Italy).  167 
 168 
2.5 Muscle biopsies and blood sampling  169 
Muscle biopsies: Muscle biopsies were performed on the vastus lateralis muscle of the 170 
participant’s dominant leg. Following injection of a local anaesthetic (2 mL, 1% Xylocaine), 171 
incisions were made and the biopsy needle inserted. Muscle samples were collected with 172 
manual suction (13). To minimalize acute changes induced by muscle biopsy procedures, a 173 
new incision was made for each muscle biopsy. Following collection, the samples (50-200 174 
mg) were immediately blotted on filter paper to remove excess blood, with a small portion 175 
(10-15 mg) immediately processed for the determination of mitochondrial respiration (15). 176 
The remaining portion of the muscle was snap-frozen in liquid nitrogen and stored at −80 ˚C 177 
for subsequent analysis.  178 
Blood sampling: Venous blood samples were collected through cannulation immediately after 179 
each muscle biopsy (22). Five millilitres of venous blood were collected with BD Vacutainer 180 
EDTA blood collection tubes (Becton, Dickinson and Company, USA); the tubes were then 181 
inverted 6-10 times, centrifuged at 3,500 rpm for 10 minutes at 4˚C, and the resulted 182 
supernatant plasma samples were collected and aliquoted into Eppendorf tubes. The residual 183 
blood was saved for DNA extraction.  184 
 185 
2.6 Muscle and blood analysis 186 
Genotyping 187 
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Genomic DNA was extracted from residual blood samples using the GeneJET Genomic 188 
Whole Blood DNA Purification Kit (#K0781 Thermo Scientific, MA, USA), as well as using 189 
the MagSep Blood gDNA Kit (Eppendorf, Hamburg, Germany). ACE I/D genotypes were 190 
determined using the TaqMan SNP assay (rs4343, Applied Biosystems, Foster City, 191 
California, United States) by Mastercycler® ep realplex2 (Eppendorf, Hamburg, Germany), 192 
and QuantStudio™ 7 Flex Real-Time PCR System (Applied Biosystems, Foster City, 193 
California, United States). Genotyping was validated by another researcher with a new set of 194 
DNA samples (41). 195 
Plasma ACE content analysis 196 
For quantitation of ACE enzyme content in plasma, Abcam Human ELISA Kit (ab119577 –197 
ACE (CD143)) was used (Abcam, Cambridge, United Kingdom). All samples were stored in 198 
-80 °C freezer before analysis. After thawing on ice, plasma samples were diluted 50 times 199 
with sample diluent buffer. 100µl of diluted samples were added to plate in duplicates, sealed 200 
and incubated at 37°C for 90 minutes. 100 µL of 1X Biotinylated Anti-Human ACE antibody 201 
was added into each well and the plate was incubated another 60 minutes at 37°C. The plate 202 
was then washed three times with 300 µL 0.01 M PBS (8.5 g NaCl, 1.4 g Na2HPO4 and 0.2 203 
g NaH2PO4 added to 1L distilled water, and pH adjusted to 7.2 - 7.6). 100 µL of 1X Avidin-204 
Biotin-Peroxidase Complex working solution was added into each well and the plate was 205 
incubated at 37°C for 30 minutes. The plate was then washed five times with 0.01M PBS, 90 206 
μL of prepared TMB Colour Developing Agent were added into each well and the plate was 207 
incubated at 37°C avoiding light for 25 minutes. 100 µL of prepared TMB Stop Solution was 208 
added into each well. The O.D. absorbance at 450 nm was obtained with a microplate reader 209 
within 15 minutes after adding the stop solution.  210 
Western blots  211 
Approximately 15 mg of frozen muscle samples were homogenized in ice-cold 212 
RadioImmunoPrecipitation Assay (RIPA) lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM 213 
NaCl, 0.5% Sodium Deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM EDTA with 214 
protease/phosphatase inhibitors, 1 mM PMSF, 1 g/mL Aprotinin, 1 g/ml Leupeptin, 1mM 215 
Benzamidine, 1 mM Na3VO4, 5 mM Na Pyrophosphate, 1 mM DTT, 1 mM NaF and 216 
proteinase/phosphatase inhibitor cocktail ) using a TissueLyser II (Qiagen, Hilden, Germany) 217 
for 2 × 1 minute at 30 Hz, and rotated for 1 h at 4°C. Muscle lysates were stored at -80°C 218 
until further analysis. Total protein content of muscle lysates was determined using the 219 
Bradford protein assay (Bio-Rad Laboratories, Hercules, United States). 220 
Protein extracts were loaded on TGX Stain-Free
TM
 Precast gels (Bio-Rad Laboratories, 221 
Hercules, United States), separated for 120 minutes at 100V and subsequently transferred to 222 
PolyVinyl DiFluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, United States) 223 
using a Trans-Blot ® Turbo™ Transfer System (Bio-Rad Laboratories, Hercules, United 224 
States). Thereafter, blots were blocked for 60 minutes in 5% milk in tris-buffered saline 225 
(TBS) and washed with TBS plus 0.1% Tween at room temperature, followed by incubation 226 
with ACE, UCP2 and UCP3 primary antibodies (1:1000 dilution) overnight at 4˚C. After 227 
washing, the membranes were incubated with the appropriate secondary antibodies for 60 228 
minutes at room temperature and revealed using a chemiluminescent substrate (Bio-Rad 229 
Laboratories, Hercules, United States). Light emission was recorded using ChemiDocTM MP 230 
System (Bio-Rad Laboratories, Hercules, United States) and quantified by image analysis 231 
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software (Image Lab, Bio-Rad Laboratories, Hercules, United States). Protein content was 232 
then normalized to total protein analysis by TGX Stain-Free
TM
 gel (Bio-Rad Laboratories, 233 
Hercules, United States) (Eaton et al., 2013). 234 
2.7 Data analysis 235 
We used robust linear models adjusted for age to test the effect of the ACE I/D polymorphism 236 
on outcomes at baseline, using the MASS package in the R statistical software. We used linear 237 
mixed models (with the lme4 package) adjusted for age to test the effect of a single session of 238 
HIIE, and to test for a possible interaction between the ACE I/D polymorphism and a single 239 
session of HIIE, on the changes of measured outcomes immediately after and 3h post 240 
exercise. UCP3 protein levels were not normally distributed and were log transformed before 241 
running the analyses. We treated DD, ID and II genotypes as separate groups. p-values were 242 
adjusted for multiple comparisons using the Benjamini and Hochberg method, and all 243 
reported p-values are adjusted p-values. An adjusted p value < 0.005 was considered 244 
significant (3). 245 
 246 
3. Results 247 
 248 
3.1. ACE I/D gene variant is not associated with baseline fitness levels 249 
The ACE I/D genotype distribution in our sample was 27 DD, 39 ID, and 15 II individuals, 250 
which is similar to the general population. There was a trend toward higher Wpeak and LT in 251 
the DD participants compared to their ID and II counterparts. However, this trend was 252 
abolished after using a robust multiple comparison statistical approach (p = 0.072 for Wpeak 253 
and LT) (Table 1).  254 
 255 
Table 1. Physiological characteristics among different ACE I/D genotypes 256 
  DD (n=27) ID (n=39) II (n=15) Raw p-value 
Adjusted p-
value* 
Wpeak (W) 311.6 (79.8) 285.6 (52.0) 256.5 (36.7) 0.024 0.072 
LT (W) 229.6 (74.3) 206.0 (43.8) 180.9 (33.0) 0.029 0.072 
VO2peak (mL/min/kg) 48.5 (7.3) 46.1 (6.9) 42.6 (6.6) 0.37 0.37 
Data are presented as Mean ± SD. *p-value after BH correction, from a robust linear model. 257 
 258 
3.2. ACE I/D gene variant is associated with ACE content in blood, but not ACE, UCP2 259 
or UCP3 protein content in muscle at baseline 260 
We then tested whether there were any differences in ACE content in blood, and any 261 
differences in ACE, UCP3 and UCP2 protein content in muscle at baseline between the 262 
different genotypes. II individuals had only about half the amount of ACE content in blood, 263 
compared with ID and DD individuals (p = 0.000015, Table 2). However, there were no 264 
differences in ACE protein content in skeletal muscle between genotypes at baseline (p = 265 
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0.46, Table 2). Similarly, there were no differences in UCP2 or UCP3 protein content in 266 
muscle between genotypes at baseline (p = 0.084 and p = 0.46, Table 2). 267 
We next tested whether ACE content in blood is correlated with ACE content in skeletal 268 
muscle at baseline, and found no significant correlation between the two (p = 0.81, r = 0.028). 269 
We further tested the correlation between ACE blood and muscle content according to 270 
different ACE I/D genotypes. There was no correlation among DD individuals (p = 0.96, r = 271 
0.012), ID individuals (p = 0.52, r = 0.11), or II individuals (p = 0.78, r = 0.088) at baseline.  272 
 273 
Table 2. ACE content in blood, ACE, UCP2 and UCP3 content in muscle at baseline 274 
  DD (n=27) ID (n=39) II (n=15) Raw p-value 
Adjusted p-
value* 
ACE content in blood at 
baseline (pg/mL) 
4281 (1731) 4676 (1729) 2233 (607.0) 0.000015 NA 
      
ACE protein content in 
muscle at baseline 
(arbitrary unit, AU) 
1.86 (0.77) 1.58 (0.58) 1.63 (0.41) 0.23 
 
0.46 
UCP2 protein content in 
muscle at baseline (AU) 
1.3 (0.76) 1.5 (1.0) 1.1 (0.73) 0.32 0.46 
UCP3 protein content in 
muscle at baseline (AU)† 
0.91 (0.32) 1.4 (1.4) 0.88 (0.28) 0.028 0.084 
Data are presented as Mean ± SD. *p-value after BH correction, from a robust linear model. 275 
†Data were not normally distributed and were log-transformed for the statistical test 276 
 277 
3.3. A single session of HIIE reduced UCP3 protein content in muscle but did not affect 278 
ACE content in blood, or ACE and UCP2 protein content in muscle. 279 
Using a stringent adjusted p-value threshold of 0.005, there was a trend for an increase in 280 
ACE blood content immediately after exercise (mean fold change = 0.13, p = 0.0053), but no 281 
changes 3h after HIIE (p = 0.87) (Table 3 and Figure 2a). We noted a small decrease of 282 
muscle UCP3 protein content immediately after exercise (mean fold change = 0.06, p = 283 
0.0035, Table 3 and Figure 2d). There were no changes in muscle ACE or UCP2 protein 284 
content immediately or 3h post HIIE (Table 3 and Figure 2b,c). 285 
We next tested whether the changes of ACE blood content are correlated with changes of 286 
ACE content in skeletal muscle after HIIE. There was no significant correlation immediately 287 
after HIIE (p = 0.083, r = 0.20) or 3h post HIIE (p = 0.43, r = 0.094). 288 
 289 
Table 3. ACE content in  blood, ACE, UCP2 and UCP3 protein content in muscle following 290 
HIIE 291 
  Pre Post Raw p-value Adjusted p-value* 
ACE level in blood (pg/mL) 4115 (1810) 4430 (1818) 0.0053 NA 
         
ACE protein level in muscle (AU) 1.7 (0.63) 1.6 (0.64) 0.037 0.074 
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UCP2 protein level in muscle (AU) 1.4 (0.89) 1.5 (0.94) 0.11 0.11 
UCP3 protein level in muscle (AU)† 1.1 (1.0) 0.97 (0.48) 0.0012 0.0035 
     
  Pre 3HP  Adjusted p-value* 
ACE level in blood (pg/mL) 4115 (1810) 4138 (1731) 0.87 NA 
         
ACE protein level in muscle (AU) 1.7 (0.63) 1.5 (0.71) 0.0057 0.017 
UCP2 protein level in muscle (AU) 1.4 (0.89) 1.6 (1.0) 0.018 0.018 
UCP3 protein level in muscle (AU)† 1.1 (1.0) 0.99 (0.65) 0.0084 0.017 
Data are presented as Mean ± SD. *p-value after BH correction, from a robust linear model. 292 
†Data were not normally distributed and were log-transformed for the statistical test  293 
 294 
3.4. ACE I/D gene variant did not modulate the effect of HIIE on ACE, UCP2 or UCP3 295 
in blood or muscle. 296 
We then tested whether the ACE I/D polymorphism is associated with ACE level in blood, as 297 
well as ACE, UCP2 and UCP3 protein levels in muscle, following HIIE. There were no 298 
differences in response to a single bout of HIIE between the different genotypes (Table 4). 299 
We further tested the correlation between ACE blood content and skeletal muscle content 300 
according to different ACE I/D genotypes after HIIE. There was no correlation among DD 301 
individuals (p = 0.053, r = 0.41), ID individuals (p = 0.97, r = 0.0054), or II individuals (p = 302 
0.19, r = 0.41) immediately after HIIE. However, three hours post HIIE, there was a tendency 303 
for correlation among II individuals (p = 0.039, r = 0.60), but not DD (p = 0.65, r = 0.099) or 304 
ID (p = 0.44, r = -0.13) individuals.  305 
 306 
Table 4. ACE content in blood, ACE, UCP2 and UCP3 protein content in muscle after HIIE 307 
according to ACE I/D genotypes 308 
 DD ID II   
  Pre Post Pre Post Pre Post Raw p-
value 
Adjusted 
p-value 
ACE level in blood 
(pg/mL) 
4281 
(1731) 
 4488 
(1486) 
4676 
(1729) 
 4947 
(1969) 
2233 
(607.0) 
 2878 
(968.8) 
0.37 NA 
         
ACE protein content 
in muscle (AU) 
1.9 
(0.77) 
 1.7 
(0.74) 
1.6 
(0.58) 
 1.5 
(0.62) 
1.6 
(0.41) 
 1.6 
(0.51) 
0.79 0.84 
UCP2 protein content 
in muscle  (AU) 
1.3 
(0.76) 
 1.5 
(0.94) 
1.5 (1.0)  1.5 
(0.87) 
1.1 
(0.73) 
 1.2 
(1.2) 
0.42 0.84 
UCP3 protein content 
in muscle (AU) 
0.91 
(0.32) 
 0.83 
(0.23) 
1.4 (1.4)  1.1 
(0.62) 
0.88 
(0.28) 
 0.86 
(0.18) 
0.079 0.24 
         
  Pre 3HP Pre 3HP Pre 3HP Raw p-
value 
Adjusted 
p-value 
ACE level in blood 
(pg/mL) 
4281 
(1731) 
 4272 
(1511) 
4676 
(1729) 
 4635 
(1799) 
2233 
(607.0) 
 2498 
(667.2) 
0.66 NA 
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ACE protein content 
in muscle (arbitrary 
unit, AU) 
1.9 
(0.77) 
 1.6 
(0.70) 
1.6 
(0.58) 
 1.4 
(0.70) 
1.6 
(0.41) 
 1.6 
(0.76) 
0.72 0.72 
UCP2 protein content 
in muscle  (AU) 
1.3 
(0.76) 
 1.4 
(0.78) 
1.5 (1.0)  1.9 
(1.2) 
1.1 
(0.73) 
 1.0 
(0.53) 
0.098 0.29 
UCP3 protein content 
in muscle  (AU) 
0.91 
(0.32) 
 0.85 
(0.27) 
1.4 (1.4)  1.2 
(0.88) 
0.88 
(0.28) 
 0.84 
(0.19) 
0.18 0.37 
 309 
 310 
4. Discussion 311 
 312 
We explored the influence of the ACE I/D gene variant on ACE enzyme content in blood, as 313 
well as ACE, UCP2 and UCP3 protein content in human skeletal muscle, pre-and-post HIIE.  314 
We also analyzed the influence of ACE I/D polymorphism on fitness levels (Wpeak, LT, 315 
VO2peak) at baseline. In all cases, we utilized a robust statistical approach with a stringent p-316 
value (< 0.005). The ACE I/D genotype was associated with plasma ACE content; DD 317 
individuals had significantly (68%) higher ACE content at baseline compared with II 318 
individuals. A single session of HIIE tended to increase blood ACE levels immediately post 319 
exercise, while muscle ACE protein content tended to be lower 3 hours post  a single session 320 
of HIIE (0.005 < p < 0.05). Moreover, muscle UCP3 protein content decreased immediately 321 
post a single session of HIIE, and remain low 3 hours post exercise. Those changes in muscle 322 
were not ACE I/D genotype-dependent.  323 
The association between ACE genotype and baseline fitness levels 324 
The ACE I/D gene variant has previously been associated with athletic performance (24). We 325 
investigated a possible association between the ACE I/D gene variant and physiological 326 
parameters at baseline. However, we did not observe differences in Wpeak, VO2peak or LT 327 
(three strong markers of exercise performance) between DD and II participants. Our findings 328 
are consistent with previous studies in trained Polish male, and female athletes (29) and 329 
indicated that the participants were well-matched for fitness levels at baseline, regardless of 330 
their genotype. This prompted us to further investigate any ACE I/D genotype effects in the 331 
molecular level.  332 
The influence of the ACE I/D gene variant on ACE content in blood and muscle  333 
In line with the literature (33), ACE DD carriers had 68% higher ACE levels in the serum 334 
compared with ACE II carriers at baseline. Elite endurance athletes have higher frequency of 335 
the ACE II genotype, and lower frequency of the DD genotype, in some studies (31), and this 336 
has been associated with low ACE content in the blood. 20 minutes of bicycle exercise at 337 
70% VO2max also increased serum ACE enzyme activity (39). Therefore, it may be intuitive 338 
to think that an acute session of HIIE would lead to higher blood ACE level. However, we 339 
did not observe significant changes of plasma ACE content after an acute HIIE session.  340 
The ACE mRNA expression and enzyme activity are regulated by angiotensin II (Ang II). 341 
Ang II infusion significantly reduced ACE mRNA levels in the lung and in the testis, as well 342 
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as the ACE enzyme activity in plasma  (37). Plasma Ang II level increased following acute 343 
exercise (39). The regulation of ACE by Ang II is mediated, at least partly by Mitogen-344 
Activated Protein Kinase (MAPK) pathway (p38 and p42/44) (9, 20), and one session of 345 
exercise (60 min of cycling at 70% of VO2 max) activated MAPK the p42/44 MAPK 346 
signalling pathway in human skeletal muscle (1). The other possible mediator of Ang II 347 
induced downregulation of ACE is possibly UCP2, Ang II has been shown to upregulate 348 
UCP2 (42), while UCP2 has been reported to inhibit ACE expression (10).  Based on our 349 
data, we hypothesis that one session of HIIE leads to elevated ACE content and Ang II in the 350 
blood (showed here in the results section), while more Ang II enters to skeletal muscle and 351 
results in lower ACE expression in skeletal muscle.  352 
We also explored, for the first time, the association between ACE blood content and  ACE 353 
muscle content in healthy, moderately-trained individuals, and found no significant 354 
correlation both at baseline and after HIIE. The study by Reneland et al., has reported no 355 
correlation between ACE enzyme activity in blood and ACE activity in skeletal muscle 356 
among hypertensive patients (32), while an early study has also reported a discrepancy 357 
between plasma and lung angiotensin-converting enzyme activity in a rat model (16).  358 
We found no association between ACE I/D polymorphism and ACE protein content in  359 
muscle, at baseline or post exercise. Extensive literature exist on the association between 360 
ACE I/D polymorphism and athletic performance, and physiological parameters (28). 361 
However, we are not aware of any study looking at the association between ACE content in 362 
muscle and ACE content in blood according to ACE I/D polymorphism, and the possible 363 
biological mechanism(s) involved. We therefore suggest that although the RAS exists in 364 
skeletal muscle, and the ACE is expressed in muscle, it might not be affected by an acute 365 
session of HIIE; alternatively, the exercise effects on ACE muscle content may require a 366 
longer exercise intervention. We therefore suggest that future work will focus on looking at 367 
the influence of the ACE I/D polymorphism on ACE protein content after a chronic exercise 368 
intervention rather than acute one.  369 
 370 
The influence of the ACE I/D gene variant on UCP2 and UCP3 protein content in muscle 371 
Uncoupling proteins are mitochondrial transporters which regulate mitochondrial function 372 
and cellular metabolism (10). UCP2 is critical in maintaining fatty acid oxidation (21), while 373 
UCP3 is highly expressed in skeletal muscle and has been previously reported to involve in 374 
the process of mitochondrial biogenesis (19). UCP2 and 3 have a rapid turnover (2), and we 375 
therefore investigated the effect of acute HIIE on their protein content in skeletal muscle. In 376 
the present study, a single session of HIIE did not change UCP2 protein content. No studies 377 
have reported the protein content of UCP2 after acute exercise, and there is discrepancy 378 
regarding the effect of acute exercise on UCP2 gene expression. One study reported that 379 
acute exercise tended to decrease muscle UCP2 gene expression in humans (36). However, a 380 
different study reported on higher UCP2 gene expression after acute exercise in mice (7). On 381 
the other hand, UCP3 protein content significantly decreased immediately post HIIE, and 382 
remained at low-levels three hours post HIIE. This finding is different from previous studies 383 
showing no changes in UCP3 protein levels following acute exercise (14, 35). The 384 
discrepancy could be due to the different format of exercise, while previous studies employed 385 
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moderately intensity continuous exercise, we utilised high-intensity interval exercise in the 386 
present study. This decrease, however, was not ACE I/D variant-dependent.  387 
There are several possible explanations as to why our current results are different from the 388 
previously reported. Our exercise intervention consisted of short, high-intensity intervals (one 389 
session, eight bouts of 2 min exercise), which could have triggered different molecular 390 
pathways then the traditional continuous endurance exercise. Another possible explanation is 391 
that the II genotype is associated with endurance athletes only at the elite level, and not 392 
necessarily with exercise responses in moderately-trained participants. 393 
Study limitations 394 
Compared to traditional exercise studies we have assessed a relatively large number of 395 
participants (n=81 and muscle biopsies (n=81 X 3 time points). However, when divided by 396 
genotypes the numbers are still insufficient to identify a strong genotype effect. This 397 
speculation is supported by our observation that there was a tendency of changes in blood 398 
ACE content and muscle ACE, UCP2 and UCP3 protein content after acute exercise, while 399 
there was no difference after dividing participants according to ACE I/D genotypes. 400 
Furthermore, muscle biopsies, by nature, may result in damaged muscle tissue. We performed 401 
three muscle biopsies in a very short period of time, which may have resulted in repetitive 402 
tissue damage possibly led to up/down regulations of tissue repair molecular pathways. 403 
The association between the ACE I/D genotype and endurance performance has mostly been 404 
found at the high end of the performance spectrum, and our study population was 405 
recreationally active males. Becoming an elite athlete requires intensive and chronic exercise 406 
training leading to massive adaptations and extreme muscle phenotypes. It is possible that the 407 
training stimulus we utilised (a session of HIIE) was insufficient to observe influence of the 408 
ACE I/D genotype on ACE, UCP2 or UCP3 muscle content.  409 
Conclusions and future directions 410 
In conclusion, the results of the present study provide evidence of the ACE I/D genotype as a 411 
strong predictor for ACE enzyme content in the blood. However, the ACE I/D did not predict 412 
skeletal muscle ACE, UCP2 or UCP3 protein content at baseline or post HIIE. These results, 413 
combined with the absence of significant differences in baseline endurance characteristics, 414 
add to the growing body of literature suggesting that there might be other muscle targets that 415 
can explain if and why the ACE I/D influences muscle performance and adaptations to 416 
exercise training. Therefore, future studies, utilising longer periods of exercise, should focus 417 
on discovering the molecular pathways by which the ACE I/D influences exercise 418 
adaptations. Understanding both genetic/environmental contributions and how they differ 419 
between individuals could be beneficial in understanding elite performance and adaptation to 420 
training and muscle function in both healthy and diseased populations. Finally, because the 421 
ACE genotype showed strong association with ACE enzyme level in the blood, other markers 422 
in the RAS system, such as Ang II, may be worth to be measured in both blood and skeletal 423 
muscle. 424 
 425 
 426 
 427 
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Figure legends  574 
 575 
Figure 1. Study Design. Each participant underwent baseline exercise testings including two 576 
20 km Time Trials (20 km TT) and three Graded Exercise Test to exhaustion (GXTs). After a 577 
resting biopsy and blood sampling after an overnight fasting, each participant performed a single 578 
session of high-intensity interval exercise (HIIE), the second muscle biopsy and blood sample 579 
were collected immediately after HIIE. The third muscle biopsy and blood sample were 580 
collected three hours after the completion of the HIIE.  581 
 582 
 583 
Figure 2. The fold change of ACE content in blood, ACE, UCP2 and UCP3 protein content 584 
in muscle following HIIE. A. Fold change of blood ACE content after HIIE. B. Fold change 585 
of muscle ACE protein content after HIIE. C. Fold change of muscle UCP2 protein content 586 
after HIIE. D. Fold change of muscle UCP3 protein content after HIIE. 587 
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